Key facts
- This page summarizes Ann D. Rhoads's Form 4 filing for QuidelOrtho Corp (QDEL).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 01 Jun 2022, 17:39.
Ann D. Rhoads - 27 May 2022 Form 4 Insider Report for QuidelOrtho Corp (QDEL)
- Reporting relationship
- Director
- Issuer ticker
- QDEL
- Reported as of
- 27 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Jun 2022, 17:39:39 UTC
- Prior SEC filing
- 20 May 2022
- Next SEC filing
- 08 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Phillip S. Askim, attorney-in-fact for Ann D. Rhoads
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ann D. Rhoads filed Form 4 for QuidelOrtho Corp (QDEL) on 01 Jun 2022.
Change
- Previous filing in this sequence was filed on 20 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
QDEL
transaction
Common Stock
Award
- Transaction value
- Shares
- +2,248
- Change %
- Price
- Shares after
- 2,248
- Date
- 27 May 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
QDEL
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +427
- Change %
- Price
- $0.000000
- Shares after
- 427
- Date
- 27 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 427
- Exercise price
- Footnotes
- F2, F3, F4
QDEL
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +128
- Change %
- Price
- $0.000000
- Shares after
- 128
- Date
- 27 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 128
- Exercise price
- Footnotes
- F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho.
Footnote F2
Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock.
Footnote F3
Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
Footnote F4
Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.